Corporate responsibility
View all storiesTaking on Zaire ebolavirus
How science and innovation fuel our efforts to help combat a rare but potentially deadly disease
April 11, 2024
The Wall Street Journal names Merck among top 10 best-managed companies
We’re proud to be recognized for our strong performance and unwavering commitment to patients
January 11, 2024
Safeguarding the environment through green chemistry
When a manufacturing process doesn’t meet our standards, we build an award-winning, planet-friendly one
May 31, 2023
3 ways we support the LGBTQ+ community
How we stand by our commitment to allyship both within our company and in the world at large
May 11, 2023
Helping protect health from birth to adulthood
Vaccination is one of the many ways you can help protect your loved ones against certain potentially serious diseases every day
April 14, 2023
Merck recognized on Fortune’s 2022 Change the World list
Recognition highlights our continued focus on expanding access
October 25, 2022
Our partnerships help make vaccines accessible worldwide
How our colleagues are collaborating with organizations to improve global vaccination rates
October 11, 2022
Meet the inaugural Health Equity Catalyst Fund initiatives
Teams around the world will put new funding to good use helping address urgent global needs
September 9, 2022
Accelerating global access
Our company is collaborating with a range of partners to enable access for patients around the world
September 8, 2022
Merck publishes 2021/2022 Environmental, Social & Governance (ESG) Progress Report
Letter from our chief executive officer and president, Rob Davis
August 30, 2022
How we’re prioritizing supply
Learn how our teams mobilized like never before to ensure we were ready to address a global need
August 24, 2022
4 LGBTQ+ employees share stories of finding freedom to be themselves at work
Bringing your whole self to work allows you “to be happy not just in your personal life but also in your professional life"
May 26, 2022
35 Years: The Mectizan® Donation Program
The Mectizan Donation Program is the longest-running, disease-specific drug donation program of its kind
May 25, 2022
When the world needs us, together we rise to the challenge
Merck CEO & President Rob Davis shares news with colleagues about our investigational COVID-19 medicine
December 23, 2021
Giving back: How our pro bono program drives positive change
Jennifer Zachary, Merck’s General Counsel, on how we can provide more legal services to those in need
December 16, 2021
7 things you probably didn’t know about Merck
From Thomas Edison to Meryl Streep, these interesting tidbits about our company may surprise you
July 21, 2021
Merck Donates $500,000 to Support River Blindness and Lymphatic Filariasis Elimination Efforts
Grants Will Be Administered through the MECTIZAN® Donation Program and Will Support Precautionary Measures Required to Prevent the Spread of SARS-CoV-2 During Mass Drug Administration Programs for These Two Diseases Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the MECTIZAN® Donation Program (MDP), announced today a $500,000 cash donation to support non-governmental organization (NGO) partners working to eliminate river blindness (onchocerciasis) and lymphatic filariasis (LF). The funds are being provided by Merck and will be administered through an application process managed by the MDP, a public-private partnership that oversees elimination efforts of these two diseases. This funding will be offered in the form of grants to support the implementation of the World Health Organization’s (WHO’s) recommended precautionary measures to decrease the risk of the spread of SARS-CoV-2 during mass drug administration (MDA). This press release features multimedia.
October 22, 2020
Merck Issues 2019/2020 Corporate Responsibility Report
Report Demonstrates Merck’s Approach to Long-Term Sustainability for Business and Society Merck (NYSE: MRK), known as MSD outside the United States and Canada, today issued its 2019/2020 Corporate Responsibility Report . The report highlights the company’s performance and progress in its four corporate responsibility priority areas of Access to Health, Employees, Environmental Sustainability and Ethics & Values. “The multiple challenges we face as a global community in 2020 reinforce more than ever the importance of operating responsibly, following our mission of saving and improving lives and delivering sustainable value for our business and society,” said Kenneth C. Frazier, Merck chairman and chief executive officer. “At Merck, we embrace our responsibility to be a force for good in the world – not only through our medicines and vaccines but also through our broader actions to address systemic inequities and to create an environment where all people are valued and respected.”
October 14, 2020
Merck Publishes 2012 Global Corporate Responsibility Report
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today issued its 2012 global corporate responsibility report. The report, available at www.merckresponsibility.com , focuses on Merck's corporate responsibility activities, progress and performance during 2012 in four priority areas where the company is positioned to have a positive impact: Access to Health, Environmental Sustainability, Employees and Ethics and Transparency. Highlights from the 2012 report include: People reached through the company’s major responsibility programs and partnerships: 269 million Women in executive roles: 31 percent Global corporate giving: $1.7 billion Water recycled and reused during 2012: 3.3 billion gallons Reduced direct greenhouse gas emissions since 2009: Met 10 percent greenhouse gas reduction goal 3 years early Developing new partnerships to reduce maternal mortality through Merck for Mothers In addition, this year’s report provides information on the company’s commitment
July 31, 2013